Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191.
Lunn-Halbert MC, Laszlo GS, Erraiss S, Orr MT, Jessup HK, Thomas HJ, Chan H, Jahromi MA, Lloyd J, Cheung AF, Chang GP, Dichwalkar T, Fallon D, Grinberg A, Rodríguez-Arbolí E, Lim SYT, Kehret AR, Huo J, Cole FM, Scharffenberger SC, Walter RB.
Lunn-Halbert MC, et al. Among authors: kehret ar.
Cancers (Basel). 2024 Feb 22;16(5):877. doi: 10.3390/cancers16050877.
Cancers (Basel). 2024.
PMID: 38473239
Free PMC article.